BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Prurigo Nodularis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Prurigo Nodularis\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07883213-1281@assetmemo.bio
DTSTAMP:20261121T005415Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:AK139: Phase 2 readout est. (NCT07883213)
DESCRIPTION:AK139\, phase 2\, Prurigo Nodularis.\nStudy: A Study to Evaluat
 e the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.\nEs
 timated primary completion: August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ak139#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07883213
URL:https://assetmemo.bio/drug/ak139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06293053-1356@assetmemo.bio
DTSTAMP:20261121T005415Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT06293053)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Prurigo Nodularis.\nStudy: A S
 tudy to Investigate the Pharmacokinetics and Safety of Dupilumab in Partic
 ipants ≥6 Months to <18 Years of Age With Prurigo Nodularis\nEstimated p
 rimary completion: 28 October 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dupilumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06293053
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
